Pro-tumorigenic effects and therapeutic implications of mesenchymal stem cell-derived exosomes under hypoxic conditions: a systematic review
Seddighi N., Talebi M., Shamsasenjan K., Raeisi M., Movassaghpour A.
Systematic Review, published in Discov Oncol (2026) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- Discov Oncol (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41483364
- PMCID
- PMC12864586
- DOI
- 10.1007/s12672-025-04279-0
Abstract (original English)
Background Mesenchymal stem cell (MSC)-derived exosomes revealed therapeutic ability, particularly in cancer treatment, by transferring bioactive molecules like miRNAs. Hypoxia, a common tumor condition, influences both tumor progression and MSC behavior. This review explores how hypoxic conditions affect MSC-derived exosomes and their impact on cancer-related pathways and genes. Method The current systematic review study was conducted by searching four different databases, including PubMed, Scopus, Embase, and Web of Science, using keywords such as mesenchymal stem cells, exosomes, hypoxia, cancer, and related terms. All original pre-clinical studies that focused on the role and effect of hypoxia in MSC-derived extracellular vesicles in different cancers were included. Data were collected qualitatively. Result Overall, 264 articles were identified from searching in databases, and eight of them met the eligibility criteria and were included in the current study. Among the articles, four focused on lung cancer, two on breast cancer, one on hepatocellular carcinoma, and one on Multiple Myeloma. The results indicated that MSC-derived exosomes have an enhanced effect on cell viability, migration, proliferation, and invasion of cancerous cells both in vitro and in vivo settings, and also cause a reduction in apoptosis in these cells. Besides, hypo MSC-exosomes can change the express
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.